Stock futures were little changed Wednesday following three consecutive sessions of declines for major indexes. Meanwhile, ...
The late-stage melanoma trial with Merck’s Keytruda shows both lower recurrence and less spread, with no new safety ...
ATI delivered strong, upbeat Q2 FY26 results with an over 10.6% increase in its revenue and strong margin expansion. Read ...
Moderna jumped 130% on Phase 3 melanoma trial success for Intismeran + Keytruda. Click for more on MRNA stock.
The defense sector has been outperforming quietly, and Northrop Grumman is beginning to separate itself from the pack. The ...
Strategy, Coinbase, Circle, and BitMine are riding the Bitcoin short squeeze—and two of them may be squeezing equity bears of ...
GRSE built three ships INS Dunagiri that is the second P17A Alpha stealth frigate, INS Sanshodhak, the last of the ...
SK hynix stock gains as the chipmaker unveils a $29B share buyback plan while raising its shareholder return target above 50% ...
Kospi fell 6.45% Wednesday as chip stocks slid, triggering another Korea Exchange sell-side sidecar halt on the benchmark.
Workday stock rises 5.07% to $200.30 after new AI research unit launch. Workday, Inc. unveils Workday AI Research and a PhD ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results